CELC·Nasdaq·US
Celcuity
Celcuity is a clinical-stage biotechnology company developing targeted cancer therapies, led by gedatolisib for advanced breast cancer and metastatic castration-resistant prostate cancer. It also develops cellular analysis and companion diagnostic technology through its CELx platform, with no reported product revenue to date.
Recent Activity
Updated Oct 31, 2026
–Celcuity presented updated results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study in HR+/HER2- advanced breast cancer at the ESMO Congress 2026.
–In that cohort, median progression-free survival was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet, versus 9.1 months with alpelisib plus fulvestrant.
–Celcuity presented updated Phase 1b/2 data at ESMO 2026 on gedatolisib plus darolutamide in men with metastatic castration-resistant prostate cancer.
–In patients who received prior abiraterone, median radiographic progression-free survival was 15.7 months and the six-month rPFS rate was 82.2%.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.
Recent Discoveries
Recent discoveries are part of the Pro plan.